natgillin/translations-raw huggingface dataset:
The treatment duration was 6 months.
Zdravljenje je trajalo 6 mesecev.
The treatment duration was for an additional 6 or 12 months in patients who had completed 6 to 12 months of treatment for venous thromboembolism depending on the clinical judgment of the investigator.
Zdravljenje je trajalo dodatnih 6 ali 12 mesecev pri bolnikih, ki so bili predhodno že 6 ali 12 mesecev zdravljeni zaradi venske trombembolije odvisno od klinične presoje raziskovalca.
The treatment duration was from 3 months up to 12 months, determined by the investigator based on the patient’s clinical features.
Zdravljenje je trajalo od 3 mesecev do 12 mesecev, trajanje je določil raziskovalec na podlagi bolnikove klinične slike.
The treatment effect as assessed by BCVA at day 90 was thus supported by this anatomical finding.
Ta anatomska ugotovitev je podprla učinek zdravljenja, ki so ga ocenili z BCVA na 90. dan.
The treatment effect of ibandronic acid was further assessed in an analysis of the subpopulation of patients who, at baseline, had a lumbar spine BMD T-score below –2.5 (table 4).
Učinek zdravljenja z ibandronsko kislino so nadalje proučevali v analizi podskupine bolnikov, katerih T-vrednost MKG ledvene hrbtenice je bila na začetku zdravljenja pod –2,5 (preglednica 4).
The treatment effect of ticagrelor over clopidogrel appears consistent across many subgroups, including weight; sex; medical history of diabetes mellitus, transient ischaemic attack or non- haemorrhagic stroke, or revascularisation; concomitant therapies including heparins, GpIIb/IIIa inhibitors and proton pump inhibitors (see section 4.5); final index event diagnosis (STEMI, NSTEMI, or UA); and, treatment pathway intended at randomisation (invasive or medical).
Kot kaže, je ta terapevtski učinek tikagrelorja pred klopidogrelom stalen po številnih podskupinah, vključno s telesno maso, spolom, zdravstveno anamnezo ali sladkorno boleznijo, tranzitorno ishemično atako ali nehemoragično možgansko kapjo oz. revaskularizacijo, sočasnimi zdravili (vključno s heparini, zaviralci GpIIb/IIIa in zaviralci protonske črpalke; glejte poglavje 4.5), diagnozo končnega indeksnega dogodka (STEMI, NSTEMI ali nestabilna AP) ter terapevtske poti, nameravane pri randomizaciji (invazivna ali neinvazivna).
The treatment effect of ticagrelor over clopidogrel appears consistent across many subgroups, including weight; sex; medical history of diabetes mellitus, transient ischaemic attack or non-haemorrhagic stroke, or revascularisation; concomitant therapies including heparins, GpIIb/IIIa inhibitors and proton pump inhibitors (see section 4.5); final index event diagnosis (STEMI, NSTEMI, or UA); and treatment pathway intended at randomisation (invasive or medical).
Kot kaže, je ta terapevtski učinek ticagrelorja pred klopidogrelom stalen po številnih podskupinah, vključno s telesno maso, spolom, zdravstveno anamnezo sladkorne bolezni, tranzitorno ishemično atako ali nehemoragično možgansko kapjo oz. revaskularizacijo, sočasnimi zdravili (vključno s heparini, zaviralci GpIIb/IIIa in zaviralci protonske črpalke; glejte poglavje 4.5), diagnozo končnega indeksnega dogodka (STEMI, NSTEMI ali nestabilna AP) ter terapevtske poti, nameravane pri randomizaciji (invazivna ali neinvazivna).
The treatment effect of vorapaxar on the primary and key secondary endpoints was shown to be durable and persistent over the length of the TRA 2°P - TIMI 50 study.
Učinek zdravljenja z vorapaksarjem na primarne in ključne sekundarne opazovane dogodke se je izkazal za obstojnega in trajnega med celotnim trajanjem študije TRA 2°P – TIMI 50.
The treatment failure rate using the same composite end-point with centrally read BPAR was 1.9% in the Envarsus group and 3.7% in the Prograf group (95% confidence interval [-6.51%, 2.31%]).
Stopnja izgube učinkovitosti, izmerjena kot enak sestavljen opazovani dogodek s centralno določeno BPAR, je bila 1,9 % v skupini z zdravilom Envarsus in 3,7 % v skupini z zdravilom Prograf (95-odstotni interval zaupanja [-6,51 %; 2,31 %]).
The treatment free period, however, should take into account the pharmacological properties of the products used previously.
Poleg tega je treba pri določanju obdobja brez zdravil upoštevati farmakološke lastnosti zdravil, ki smo jih dajali predhodno.
The treatment indirectly reduces the risk of transmission of tick-borne diseases (canine babesiosis, monocytic ehrlichiosis, granulocytic anaplasmosis and borreliosis) from infected ticks for 4 weeks.
Zdravljenje 4 tedne zmanjšuje tveganje za prenos s klopi prenosljivih bolezni (babezioza psov, monocitna erlihioza, granulocitna anaplazmoza in borelioza).
The treatment initiation pack contains 27 film- coated tablets (4 x10 mg, 4x 20 mg, 19 x 30 mg).
Pakiranje za začetek zdravljenja vsebuje 27 filmsko obloženih tablet (4 x 10 mg, 4x 20 mg, 19 x 30 mg).
The treatment initiation pack contains one green pen for Lyxumia 10 micrograms and one purple pen for Lyxumia 20 micrograms.
Pakiranje za uvedbo zdravljenja vsebuje en zelen peresnik z zdravilom Lyxumia 10 mikrogramov in en škrlaten peresnik z zdravilom Lyxumia 20 mikrogramov.
The treatment initiation pack is a folding wallet containing 27 tablets: 4 x 10 mg tablets, 4 x 20 mg tablets and 19 x 30 mg tablets.
Pakiranje za začetek zdravljenja je zgibanka, ki vsebuje 27 tablet: 4 x 10 mg tablete, 4 x 20 mg tablete and 19 x 30 mg tablet.
The treatment is continued as long as the patient continues to benefit from it without too many side effects.
Zdravljenje traja tako dolgo, dokler še koristi bolniku in ne povzroča preveč neželenih učinkov.
The treatment lasts between three and 14 days, depending on the type and the severity of the infection.
Zdravljenje traja od tri do 14 dni, odvisno od vrste okužbe in njene resnosti.
The treatment length is up to 14 days.
Zdravljenje traja do 14 dni.
The treatment may be repeated every three months depending on the patient’s symptoms.
Zdravljenje je mogoče ponoviti vsake tri mesece glede na bolnikove simptome.
the treatment of adult men with metastatic castration-resistant prostate cancer who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5.1) the treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel therapy.
zdravljenje odraslih moških z metastatskim, proti kastraciji odpornim rakom prostate, ki so asimptomatski ali blago simptomatski po nedelovanju zdravljenja z odtegnitvijo androgena , pri katerih kemoterapija še ni klinično indicirana (glejte poglavje 5.1), zdravljenje odraslih moških z metastatskim, proti kastraciji odpornim rakom prostate, pri katerih je bolezen med zdravljenjem ali po zdravljenju z docetakselom napredovala.
The treatment of hormone-dependent urinary incontinence due to sphincter mechanism incompetence in ovariohysterectomised bitches.
Zdravljenje hormonsko odvisne urinske inkontinence, ki je posledica nepravilnega delovanja sfinkterskega mehanizma pri psicah po ovariohisterektomiji.
the treatment of metastatic castration resistant prostate cancer in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5.1) the treatment of metastatic castration resistant prostate cancer in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.
za zdravljenje na kastracijo odpornega metastatskega raka prostate pri odraslih bolnikih, ki nimajo simptomov ali imajo blage simptome po neuspešnem zdravljenju z deprivacijo androgenov in pri katerih kemoterapija še ni klinično indicirana (glejte poglavje 5.1). za zdravljenje na kastracijo odpornega metastatskega raka prostate pri odraslih bolnikih, pri katerih je bolezen napredovala med ali po zdravljenju s kemoterapijo z docetakselom.
The treatment of patients with a creatinine clearance below 30 ml/min with MIRAPEXIN prolonged- release tablets is not recommended as no data are available for this patient population.
Bolnikom s kreatininskim očistkom manjšim od 30 ml/min, ne priporočamo zdravljenja z MIRAPEXIN tabletami s podaljšanim sproščanjem, ker za to skupino bolnikov ni podatkov.
The treatment of patients with a creatinine clearance below 30 ml/min with Oprymea prolonged- release tablets is not recommended as no data are available for this patient population.
Bolnikom s kreatininskim očistkom manjšim od 30 ml/min, ne priporočamo zdravljenja z Oprymea tabletami s podaljšanim sproščanjem, ker za to skupino bolnikov ni podatkov.
the treatment of pulmonary arterial
PDE-5 (za zdravljenje motenj
the treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with MTX. the treatment of moderate to severe active RA in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease- modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.
hudega, aktivnega in napredujočega revmatoidnega artritisa (RA) pri odraslih, ki se predhodno niso zdravili z metotreksatom; zmerno do hudo aktivnega revmatoidnega artritisa pri odraslih bolnikih, ki se niso zadostno odzvali na predhodno zdravljenje z enim ali več imunomodulirajočimi antirevmatičnimi zdravili ali zaviralci tumorje nekrotizirajočega faktorja (TNF) ali takšnega zdravljenja niso prenašali.
the treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with MTX. the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.
hudega, aktivnega in napredujočega revmatoidnega artritisa (RA) pri odraslih, ki se predhodno niso zdravili z metotreksatom; zmerno do hudo aktivnega revmatoidnega artritisa pri odraslih bolnikih, ki se niso zadostno odzvali na predhodno zdravljenje z enim ali več imunomodulirajočimi antirevmatičnimi zdravili ali zaviralci tumorje nekrotizirajočega faktorja (TNF) ali takšnega zdravljenja niso prenašali.
The treatment of your child has been initiated by a physician who has expertise in the diagnosis, treatment and management of infantile haemangioma.
Z zdravljenjem vašega otroka je začel zdravnik, ki je strokovnjak za diagnosticiranje, zdravljenje in ravnanje z infantilnim hemangiomom.
The treatment provides persistent repellent (anti-feeding) activity.
Zdravilo ima obstojen repelentni (proti hranilni) učinek.
The treatment regimen studied (continuous use of Rapamune in combination with calcineurin inhibitor) is not indicated for adult or paediatric patients (see section 4.1).
Preučevana shema zdravljenja (kontinuirana uporaba zdravila Rapamune sočasno z zaviralcem kalcinevrina) ni indicirana za odrasle ali pediatrične bolnike (glejte poglavje 4.1).
The treatment schedule should be based on individual veterinary diagnosis and on the local epidemiological situation.
Zdravljenje poteka glede na individualne diagnoze veterinarja in glede na lokalne epidemiološke razmere.
The treatment schedule should be based on the local epidemiological situation.
Program zdravljenja pripravimo glede na lokalno epidemiološko stanje.
The treatment schedule should be based on veterinary diagnosis and on the local epidemiological situation.
Razpored zdravljenja bi moral temeljiti na diagnozi veterinarja in lokalni epidemiološki situaciji.
The treatment scheme is also indicated on the treatment initiation pack.
Da bi zmanjšali nevarnost pojava neželenih učinkov, odmerek dosegate postopoma, po priporočilu sledeče sheme dnevnega odmerjanja:
The treatment should be discontinued if a patient continues to experience any of these reactions at 20 mg/m2.
Če se bolniku še vedno pojavlja kateri od teh učinkov tudi pri odmerku 20 mg/m2, je treba zdravljenje prekiniti.
The treatment should be discontinued if any of these signs are observed: repeated diarrhoea, vomiting, faecal occult blood, sudden weight loss, anorexia, lethargy, degradation of renal or hepatic biochemistry parameters.
Če se pojavijo stranski učinki kot so bruhanje, ponavljajoča se driska, kri v blatu, nenadna izguba telesne mase, anoreksija, letargičnost, spremenjene vrednosti biokemičnih parametrov ledvic ali jeter, takoj prenehajte z uporabo tega zdravila.
The treatment should be either discontinued or stopped in the following situations:
Zdravljenje je potrebno prekiniti ali z njim prenehati v naslednjih primerih:
The treatment should be initiated and supervised by specialists experienced in the treatment of rheumatoid arthritis.
Zdravljenje lahko prične in nadzira le specialist, ki ima izkušnje pri zdravljenju revmatoidnega artritisa.
The treatment should be maintained until patients are fully mobilized.
Z uporabo zdravila je treba nadaljevati, dokler ni bolnik znova popolnoma mobiliziran.
The treatment should be re-considered if at 5 days no improvement in the clinical condition is observed.
O zdravljenju moramo ponovno presoditi, če se po 5 dneh klinično stanje ne izboljša.
The treatment should be reconsidered if at 5 days no improvement in the clinical condition is observed.
O zdravljenju moramo ponovno presoditi, če se po 5 dneh klinično stanje ne izboljša.
The treatment should be reconsidered if no improvement of the clinical condition is observed within 3 days after starting the treatment.
Če se klinično stanje ne izboljša v 3 dneh po začetnem zdravljenju, je potrebno o zdravljenju ponovno razmisliti.
The treatment should not be initiated when the patients have existing cytogenetic abnormalities of chromosome 7.
Bolnikom s prisotno citogenetsko nepravilnostjo kromosoma 7 se zdravljenja ne sme uvesti.
The treatment should start with 62.5 micrograms (a quarter of the dose) every other day, increasing progressively over 19 days to reach the recommended dose of 250 micrograms (8 MIU) given every other day.
Zdravljenje se začne z 62,5 mikrograma (četrtino odmerka), ki se injicira vsak drugi dan, ta odmerek pa se v naslednjih 19 dneh postopoma povečuje do priporočenega odmerka 250 mikrogramov (8 milijonov i.e.), ki se daje vsaki drugi dan.
The treatment will be given by your doctor or other health care provider by infusing a dilution of the Soliris vial from a drip bag through a tube directly into one of your veins.
Zdravilo vam bo dajal zdravnik ali drug zdravstveni delavec z infundiranjem razredčene vsebine viale zdravila Soliris iz infuzijske vrečke skozi cevko neposredno v eno od ven.
The treatment with Defitelio can be initiated and continuously supervised only by an experienced doctor in an hospital or in a specialised centre for stem cells transplantation.
Zdravljenje z zdravilom Defitelio lahko uvede in stalno nadzoruje samo izkušen zdravnik v bolnišnici ali specializiranem centru za presaditev matičnih celic.
The treatment with Fareston should only be stopped when advised by your doctor.
Zdravljenje z zdravilom Fareston smete prekiniti le po nasvetu zdravnika.
The treatment with Silodyx may lead to an abnormal ejaculation (decrease in the amount of semen released during sex) that may temporarily affect male fertility.
Zdravljenje z zdravilom Silodyx lahko povzroči nenormalno ejakulacijo (zmanjšanje količine sperme, izločene pri spolnem odnosu), kar lahko začasno prizadene moško plodnost.
The treatment with this medicine is not recommended if you have a severe liver disease or severe kidney disease.
Če imate hudo bolezen jeter ali ledvic, zdravljenje s tem zdravilom ni priporočljivo.
The treatment with Urorec may lead to an abnormal ejaculation (decrease in the amount of semen released during sex) that may temporarily affect male fertility.
Zdravljenje z zdravilom Urorec lahko povzroči nenormalno ejakulacijo (zmanjšanje količine sperme, izločene pri spolnem odnosu), kar lahko začasno prizadene moško plodnost.
The treatment with Vimpat starts usually with a dose of 100 mg daily given half (50 mg) in the morning and half (50 mg) in the evening.
Zdravljenje z zdravilom Vimpat se običajno začne z odmerkom 100 mg na dan, tako da prejmete pol (50 mg) odmerka zjutraj in drugo polovico (50 mg) zvečer.
The treatment- free period should take into account the pharmacological properties of the medicinal products used previously.
Ob prekinitvi zdravljenja upoštevajte lastnosti drugih zdravil, ki ste jih dajali pred tem.
The treatment- free period should take into account the pharmacological properties of the products used previously.
Ob prekinitvi zdravljenja upoštevajte lastnosti drugih zdravil, ki ste jih dajali pred tem.
The treatment-experienced subjects studied were primarily pegIFN/RBV null responders.
V raziskavo vključeni preiskovanci, ki so že bili zdravljeni, so bili primarno neodzivni na pegIFN/RBV.
The treatment-free period should take into account the pharmacological properties of the products used previously.
Za obdobje brez zdravljenja je potrebno upoštevati farmakološke lastnosti drugih zdravil, ki ste jih dajali pred tem.
The treatment-free period, however, should take into account the pharmacokinetic properties of the products used previously.
Pri določanju časa, v katerem ne smemo dajati drugih zdravil, je treba upoštevati tudi farmakokinetične lastnosti teh zdravil.
The treatment-free period, however, should take into account the pharmacokinetic properties of the products used previously.
Pri določitvi časa, ki mora miniti od prenehanja zdravljenja s prejšnjim zdravilom in pričetkom zdravljenja z zdravilom Previcox, moramo upoštevati farmakokinetične lastnosti prejšnjega zdravila.
The treatment-free period, however, should take into account the pharmacokinetic properties of the products used previously.
V tem obdobju moramo upoštevati farmakokinetične lastnosti prej uporabljenih zdravil.
The treatment-free period, however, should take into account the pharmacokinetic properties of the veterinary products used previously.
Poleg tega je treba pri določanju obdobja brez zdravil upoštevati farmakokinetične lastnosti zdravil, ki smo jih dajali predhodno.
The treatment-free period, however, should take into account the pharmacological properties of the products used previously.
Poleg tega je treba pri določanju obdobja brez zdravil upoštevati farmakokinetične lastnosti zdravil, ki smo jih dajali predhodno.
The treatment-free period, however, should take into account the pharmacological properties of the products used previously.
Poleg tega je treba v obdobju brez zdravljenja upoštevati farmakološke lastnosti zdravil, ki ste jih dajali predhodno.
The treatment-free period, however, should take into account the pharmacological properties of the products used previously.
Pri določanju obdobja brez zdravljenja ustrezno upoštevajte farmakološke lastnosti predhodno uporabljenih zdravil.
The treatment-free period, however, should take into account the pharmacological properties of the veterinary medicinal products used previously.
Poleg tega je treba v obdobju brez zdravljenja upoštevati farmakološke lastnosti zdravil, ki ste jih dajali predhodno.
The treatment-free period, however, should take into account the pharmacological properties of the veterinary products used previously.
Poleg tega je treba pri določanju obdobja brez zdravil upoštevati farmakološke lastnosti zdravil, ki smo jih dajali predhodno.
The treatment-free period, however, should take into account the pharmacological properties of veterinary medicinal products used previously.
Poleg tega je treba pri določanju obdobja brez zdravil upoštevati tudi farmakokinetične lastnosti tistih zdravil, ki so bila uporabljena predhodno.
The treatment-free period, however, should take into account the pharmacological properties of veterinary medicinal products used previously.
Poleg tega je treba pri določanju obdobja brez zdravil upoštevati tudi farmakokinetične lastnosti zdravil, ki so bila uporabljena predhodno.
The treatment-related mortality/non-relapse mortality (TRM/NRM) reported until day+100 post- transplant has also been examined through a review of published data from clinical trials.
Prav tako so s pregledom objavljenih podatkov kliničnih preskušanj proučili z zdravljenjem povezano umrljivost/umrljivost, nepovezano s ponovitvijo bolezni (ZPU/UNP), zabeleženo do dneva + 100 po transplantaciji.
The treatment-related mortality/non-relapse mortality (TRM/NRM) reported until day+100 post- transplant has also been examined through a review of published data from clinical trials.
S pregledom objavljenih podatkov kliničnih preskušanj so preiskali tudi z zdravljenjem povezano smrtnost in smrtnost, ki ni povezana s ponovitvijo bolezni (treatment-related mortality/non-relapse mortality [TRM/NRM]) do 100. dneva po transplantaciji.
The treatments were similar in the sub-group of patients with platinum-refractory disease: HR of 1.069 (95% CI: 0.823; 1.387), p=0.618. The survival rates at 1, 2 and 3 years were 41.5%, 21.1% and 13.8% respectively on Caelyx, compared to 43.2%, 17.2% and 9.5% on topotecan.
Stopnje preživetja za Caelyx so bile po 1 letu 41,5%, po 2 letih 21,1% in po 3 letih 13,8%, v primerjavi z ustreznimi stopnjami za topotekan, ki so bile 43,2%, 17,2% in 9,5%.
The trial demonstrated a statistically significant improvement in OS for patients randomised to nivolumab as compared with docetaxel at the prespecified interim analysis when 413 events were observed (93% of the planned number of events for final analysis).
Pri vnaprej predvideni vmesni analizi po 413 opaženih dogodkih (93 % predvidenega števila dogodkov za končno analizo) je preskušanje pokazalo statistično pomembno izboljšanje celokupnega preživetja pri bolnikih, randomiziranih na nivolumab, v primerjavi z docetakselom.
The trial demonstrated a statistically significant improvement in OS for patients randomised to nivolumab as compared with everolimus at the prespecified interim analysis when 398 events were observed (70% of the planned number of events for final analysis) (Table 9 and Figure 7).
Pri vnaprej predvideni vmesni analizi po 398 opaženih dogodkih (70 % predvidenega števila dogodkov za končno analizo) je preskušanje pokazalo statistično pomembno izboljšanje celokupnega preživetja pri bolnikih, randomiziranih na nivolumab, v primerjavi z everolimusom (preglednica 9 in slika 7).
The trial demonstrated non-inferiority of MabThera to cyclophosphamide for complete remission (CR) at 6 months (Table 14).
Preskušanje je dokazalo neinferiornost zdravila MabThera v primerjavi s ciklofosfamidom glede popolne remisije po 6 mesecih (preglednica 14).
The trial excluded patients with autoimmune disease; a medical condition that required immunosuppression; or who had received more than 30 Gy of thoracic radiation within the prior 26 weeks.
V preskušanje niso bili vključeni bolniki z avtoimunsko boleznijo, bolniki z zdravstvenim stanjem, ki je zahtevalo imunosupresijo, in bolniki, ki so bili v zadnjih 26 tednih zdravljeni z več kot 30 Gy obsevanja na predel prsnega koša.
The trial met its primary objective of PFS improvement.
Preskušanje je doseglo primarni cilj: podaljšanje preživetja brez napredovanja bolezni.
The trial met its primary objective of PFS improvement.
Študija je dosegla primarni cilj izboljšanja preživetja brez napredovanja bolezni.
The trial was designed to assess the clinical efficacy and safety of ONIVYDE monotherapy or ONIVYDE+5-FU/LV compared to an active control arm of 5-FU/LV.
Preskušanje je bilo zasnovano za ocenjevanje klinične učinkovitosti in varnosti zdravila ONIVYDE v monoterapiji ali zdravila ONIVYDE+5-FU/LV v primerjavi z aktivno kontrolno vejo 5-FU/LV.
The trials demonstrated that glycaemic control (HbA1c) with Levemir is comparable to NPH insulin and insulin degludec when given as basal-bolus therapy, using a non- inferiority margin of 0.4%.
Vsa preskušanja so pokazala, da je urejenost glikemije (HbA1c) z zdravilom Levemir primerljiva tisti z insulinom NPH in insulinom degludek, če je uporabljen v bazalno-bolusnem zdravljenju; uporabljena meja neinferiornosti je bila 0,4 %.
The trials included 167 children aged 1-5 years, 260 aged 6-11 and 285 aged 12-17.
V preskušanji je bilo vključenih 167 otrok, starih 1 – 5 let, 260, starih 6 – 11 let, in 285, starih 12 – 17 let.